【摘要】 目的:探讨文拉法辛与帕罗西汀治疗焦虑抑郁共病障碍的疗效及安全性。方法:73例焦虑抑郁共病障碍患者随机分为研究组35例和对照组38例。分别给予文拉法辛和帕罗西汀治疗8周。于治疗前后分别采用汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)及治疗中出现的症状量表(TESS)评定疗效和不良反应。结果:两组抗抑郁显效率(χ2=0.69,P>0.05)和抗焦虑显效率(χ2=0.90,P>0.05)相仿。两组HAMD、HAMA治疗后均显著下降(P<0.05或P<0.01)。不良反应均轻微(P>0.05)。结论:文拉法辛与帕罗西汀治疗焦虑抑郁共病障碍疗效肯定,安全性高,依从性好。更多还原

【Abstract】 Objective:To detect the efficacy and safety of venlafaxine and proxetine in the treatment of depression comorbid with anxiety.Method:73 patients with anxiety and depression were divided randomly into two groups(35 cases in study group;38 cases in control group).The study group was taken venlafaxine,and the control group was taken paroxitine.They were observed for 8 weeks.Hamilton depression scale(HAMD),Hamilton anxiety scale(HAMA)and treatment emergent symptoms scale(TESS)were used to evaluate the efficacies and side effects.Results:After 8 weeks treatment,study group showed improvement rate for depression and for anxiety which was similar to in control group(χ2=0.69,0.90;P>0.05).The two groups showed significant decreases on HAMD and HAMA scores(P<0.05 or P<0.01)and light side effects.Conclusion:Venlafaxine and paroxitine have definite efficacy and safety for combined anxiety and depression with better patients’ compliance.更多还原